Grindeks

From Wikipedia, the free encyclopedia
Jump to navigation Jump to search

AS Grindeks
Public
Traded as Nasdaq BalticGRD1R
Industry Pharmaceuticals
Founded 11 October 1991[1]
Headquarters Riga, Latvia
Area served
Worldwide
Key people
Kirovs Lipmans (Chairman)[2]
Juris Bundulis (CEO)
Janis Romanovskis (Chief Finance and Administrative Officer)
Revenue 132,4 million (2017)[3]
Increase 10.3 million (2017)[3]
Owner Kirovs Lipmans (33.29%))[2]
Anna Lipmane (16.65%)[2]
Number of employees
1355 (2017)[4]
Website grindeks.lv

AS Grindeks (branded as Grindex), is a Latvian company listed on the Nasdaq Riga with production of pharmaceutical drugs, medicine and phytochemical medicine. The company was founded 17 October 1991 and is a joint stock company since 25 August 1997.[1]

One of the key drugs for Grindeks is meldonium, marketed under the trade name Mildronate.[5][6][7] Meldonium is used for the treatment of angina and myocardial infarction by inhibiting the carnitine biosynthesis pathway via the inhibition of gamma-butyrobetaine dioxygenase.[8][9][10][11][12]

In 2017, Grindeks had a turnover revenue of 132.4 million with a profit of €10.3 million.[3] Grindeks had 1355 employees[4] and the main shareholders were Kirovs Lipmans (33.29%) and Anna Lipmane (16.65%)[2]

Main building of the company

References[edit]

  1. ^ a b "Joint Stock Company "Grindeks" Annual Report 2015" (PDF). nasdacomxbaltic.com. 2010-04-27. p. 3. Retrieved 2010-11-01. 
  2. ^ a b c d "Joint Stock Company "Grindeks" Annual Report 2015" (PDF). nasdacomxbaltic.com. p. 5. Retrieved 2016-11-01. 
  3. ^ a b c "Joint Stock Company "Grindeks" Annual Report 2015" (PDF). nasdacomxbaltic.com. p. 7. Retrieved 2016-11-01. 
  4. ^ a b "Joint Stock Company "Grindeks" Annual Report 2015" (PDF). nasdacomxbaltic.com. p. 34. Retrieved 2010-11-01. 
  5. ^ Biotech Intelligence. http://www.biotech-intelligence.com/html/html/pool_7/91cc83b0e3f8b4edbbda2a42ae43e1b1.html (accessed 17 May 2012).
  6. ^ PMR. Pharmaceutical, Healthcare and Medical Sector in Central and Eastern Europe: Industry News, Analyses and Market Data. "Archived copy". Archived from the original on 28 July 2012. Retrieved 13 June 2012.  (accessed 17 May 2012).
  7. ^ Evaluate Pharma. "Archived copy". Archived from the original on 17 December 2012. Retrieved 13 June 2012.  (accessed 17 May 2012).
  8. ^ Sesti C, Simkhovich BZ, Kalvinsh I, Kloner RA (March 2006). "Mildronate, a novel fatty acid oxidation inhibitor and antianginal agent, reduces myocardial infarct size without affecting hemodynamics". J. Cardiovasc. Pharmacol. 47 (3): 493–9. doi:10.1097/01.fjc.0000211732.76668.d2. PMID 16633095. 
  9. ^ Liepinsh E, Vilskersts R, Loca D, Kirjanova O, Pugovichs O, Kalvinsh I, Dambrova M (December 2006). "Mildronate, an inhibitor of carnitine biosynthesis, induces an increase in gamma-butyrobetaine contents and cardioprotection in isolated rat heart infarction". J. Cardiovasc. Pharmacol. 48 (6): 314–9. doi:10.1097/01.fjc.0000250077.07702.23. PMID 17204911. 
  10. ^ Hayashi Y, Kirimoto T, Asaka N, Nakano M, Tajima K, Miyake H, Matsuura N (May 2000). "Beneficial effects of MET-88, a gamma-butyrobetaine hydroxylase inhibitor in rats with heart failure following myocardial infarction". Eur. J. Pharmacol. 395 (3): 217–24. doi:10.1016/S0014-2999(00)00098-4. PMID 10812052. 
  11. ^ Leung IK, Krojer TJ, Kochan GT, Henry L, von Delft F, Claridge TD, Oppermann U, McDonough MA, Schofield CJ (December 2010). "Structural and mechanistic studies on γ-butyrobetaine hydroxylase". Chem. Biol. 17 (12): 1316–24. doi:10.1016/j.chembiol.2010.09.016. PMID 21168767. 
  12. ^ Tars K, Rumnieks J, Zeltins A, Kazaks A, Kotelovica S, Leonciks A, Sharipo J, Viksna A, Kuka J, Liepinsh E, Dambrova M (August 2010). "Crystal structure of human gamma-butyrobetaine hydroxylase". Biochem. Biophys. Res. Commun. 398 (4): 634–9. doi:10.1016/j.bbrc.2010.06.121. PMID 20599753. 

Template:Nasdaq Riga